Dacomitinib interactions
Full monograph for DacomitinibCheck it against another medicine
Medicines
89 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Atomoxetine Hydrochloride | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of atomoxetine, which is primarily metabolized by… | 7 sources — open the full entry |
| Brexpiprazole | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these… | 5 sources — open the full entry |
| Deutetrabenazine | Major | Metabolism | Deutetrabenazine has been associated with modest QT prolongation. Coadministration with a strong CYP450 2D6 inhibitor may increase the plasma concentrations of… | 5 sources — open the full entry |
| Dexlansoprazole | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| EsomeprazolebaseMUPS preparation | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Iloperidone | Major | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of iloperidone, which is a substrate of the isoenzymes. | 5 sources — open the full entry |
| Lansoprazole | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Naproxen Sodium + Esomeprazole Magnesium | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| OmeprazolebaseMUPS tablet | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Pantoprazole Sodium | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Rabeprazole Sodium | Major | Absorption | Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent reduction… | 2 sources — open the full entry |
| Tamoxifen Citrate | Major | Metabolism | Chronic coadministration of potent or moderate CYP450 2D6 inhibitors including certain antidepressants may reduce the effectiveness of tamoxifen. The proposed… | 35 sources — open the full entry |
| Tetrabenazine | Major | Metabolism | Tetrabenazine may cause modest prolongation of the QT interval. Coadministration with a potent CYP450 2D6 inhibitor may increase the plasma concentrations of… | 5 sources — open the full entry |
| Valbenazine Tosylate | Major | Metabolism | Coadministration with a strong CYP450 2D6 inhibitor may increase the exposure of (+)-alfa-dihydrotetrabenazine, the active metabolite of valbenazine, which may… | 2 sources — open the full entry |
| Vortioxetine Hydrobromide | Major | Metabolism | Coadministration with potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of vortioxetine, which is primarily metabolized by… | 9 sources — open the full entry |
| Amitriptyline Hydrochloride | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Amitriptyline Hydrochloride + Chlordiazepoxide | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Aripiprazole | Moderate | Metabolism | Coadministration with quinidine or other potent inhibitors of CYP450 2D6 may significantly increase the plasma concentrations of aripiprazole, which is… | 9 sources — open the full entry |
| Asenapine Maleate | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Bimatoprost + Timolol | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Brimonidine Tartrate + Timolol Maleate | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Brinzolamide + Timolol | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Carvedilol | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Chlorpheniramine Maleate | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Chlorpromazine Hydrochloride | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Clomipramine Hydrochloride | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Clozapine | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Darifenacin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of darifenacin, which is a substrate of these isoenzymes. | 2 sources — open the full entry |
| Dextromethorphan + Bupropion | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this… | 6 sources — open the full entry |
| Dextromethorphan + Phenylephrine + Triprolidine | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this… | 6 sources — open the full entry |
| Dextromethorphan + Pseudoephedrine + Triprolidine | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this… | 6 sources — open the full entry |
| Dextromethorphan Hydrobromide | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this… | 6 sources — open the full entry |
| Dextromethorphan Hydrobromide + Guaifenesin | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this… | 6 sources — open the full entry |
| Dextromethorphan Polistirex | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this… | 6 sources — open the full entry |
| Diphenhydramine + Dextromethorphan + Levomenthol | Moderate | Metabolism | Coadministration with CYP450 2D6 inhibitors may increase the plasma concentrations of dextromethorphan in patients who are extensive metabolizers of this…2 documented mechanisms | 7 sources — open the full entry |
| Diphenhydramine + Levomenthol | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Diphenhydramine Hydrochloride | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Diphenhydramine Hydrochloride + Zinc Acetate | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Dorzolamide + Timolol | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Doxepin (Oral) | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Doxepin (Topical) | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Doxorubicin Hydrochloride | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Doxorubicin Hydrochloride Liposome | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Duloxetine Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of duloxetine, which is partially metabolized by the isoenzyme… | 3 sources — open the full entry |
| Famotidine | Moderate | Absorption | INTERVAL: Coadministration with proton pump inhibitors (PPIs) may decrease the plasma concentrations of dacomitinib. The proposed mechanism is a pH-dependent… | 2 sources — open the full entry |
| Flecainide Acetate | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
| Fluoxetine Hydrochloride | Moderate | Metabolism | Coadministration with dacomitinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2D6 isoenzyme. The mechanism is reduced… | 1 sources — open the full entry |
Conditions
Conditions in which Dacomitinib needs care, as documented in this source.
Kidney Diseases
ModerateThe recommended dose of dacomitinib has not been established for patients with severe renal impairment (CrCl <30 mL/min). Caution is advised if used in these patients. No dose adjustment is recommended for patients with mild or moderate renal impairment.
1 source
- "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group (2018):
Liver Failure
ModerateThe recommended dose of dacomitinib has not been established for patients with severe hepatic impairment (total bilirubin > 3 to 10 × ULN and any AST). Caution is advised if used in these patients. No dose adjustment is recommended in patients with mild or moderate hepatic impairment.
1 source
- "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group (2018):